Stent implantation in the popliteal artery is feasible.

Original title: Treatment of Complex Atherosclerotic PoplitealArtery Disease With a New Self-Expanding Interwoven Nitinol Stent. 12-Month Results of the Leipzig SUPERA Popliteal Artery Stent Registry. Reference: Dierk Scheinert, et al. J Am Coll Cardiol Intv 2013;6:65–71

Currently, peripheral angioplasty (PTA) of the popliteal artery is a real challenge since stent implantation is controversial and the outcome of balloon angioplasty does not always present better results. The aim of this registry was to evaluate the efficacy of the SUPERA nitinol stent at one year, (IDEV Technologies, Webster, Texas), in complex popliteal obstructions.

101 patients were included between January 2008 and April 2010. They all received the SUPERA stent in the popliteal artery, this being the only inclusion criterion.

All were symptomatic with an ankle-brachial index of 0.58 ± 0.15. Half had moderate or severe calcification and stents were implanted in a total of 125. Primary permeability at 12 months was 87.7 ± 3% and the secondary was 96.5 ± 2% with a significant improvement in claudication. The ankle- brachial index also improved from 0.58 ± 0.15 at baseline to 0.97 ± 0.18 after one year (p <0.001). During follow-up a total of 10 patients died, 9 of which were from cardiovascular causes unrelated to the procedure. An acute occlusion was present in one patient and required amputation of the treated limb but he died two months later. This last patient was the only death related to the procedure as well as the only amputation. Radiological control was observed in 51 patients without stent fracture. 

Conclusion: 

At 12 months follow up, both the permeability and durability of the SUPERA stent over popliteal level were high.

Comment: 

The results encourage us to use stents in this territory but we must be aware that not all devices are equal. More studies are still needed to show the safety and efficacy of stents in the popliteal artery, while the use of a stent should be temporary to a suboptimal balloon result. 

Courtesy by Dr Carlos Fava.
Interventional Cardiologist
Favaloro Foundation. Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...